Shanghai Pharmaceuticals (HKG: 2607; SHA: 601607), a leading pharmaceutical company in China, has announced that it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for its recombinant human adenovirus type 5 in the treatment of malignant ascites. The filing for this trial was accepted for review by the bureau in April this year.
Oncolytic Adenovirus Anti-Tumor Drug Progress
The product in question is an oncolytic adenovirus anti-tumor drug, which was initially approved for marketing in China back in 2005 for the treatment of advanced nasopharyngeal carcinoma. This new approval marks a further step in the expansion of the drug’s application in oncology, specifically for patients suffering from malignant ascites.-Fineline Info & Tech
